Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
08 2021
Historique:
received: 26 09 2020
revised: 04 04 2021
accepted: 08 04 2021
pubmed: 5 6 2021
medline: 5 1 2022
entrez: 4 6 2021
Statut: ppublish

Résumé

Carbonic anhydrase IX (CA9) is important in the regulation of intra- and extracellular pH in solid tumors, contributing to cell growth and invasion. In urothelial carcinoma (UC), CA9 has been identified as a urinary marker for disease detection, but its biologic role is unknown. To date, differential gene expression patterns of CA9 in various molecular subtypes and potential effects of CA9 inhibition in UC cells are unknown. We aimed to investigate the function of CA9 and the effects of CA9 inhibition in invasive UC. Immunohistochemistry was used to assess CA9 expression in a cohort of 153 patients undergoing radical cystectomy. CA9 expression was correlated with molecular subtype by analysis of the TCGA data and of our own cohort of 223 patients with invasive UC receiving neoadjuvant chemotherapy. CA9 expression was assessed in a panel of 12 UC cell lines by Western Blot and qPCR, and multiple siRNAs were used to silence CA9 in 2 cell lines. Effects of CA9 silencing on cell growth, migration, and invasion were assessed. We also used the small molecule inhibitor U-104 to inhibit CA9 in vitro and in an orthotopic xenograft model. CA9 expression was higher in cancer tissue compared to benign urothelium and was particularly highly expressed in luminal papillary and basal squamous tumors. CA9 expression did not correlate with outcome after neoadjuvant chemotherapy and/or radical cystectomy. Silencing of CA9 by siRNA diminished invasion but did not induce a consistent change of cell growth and migration. Treatment with U-104 led to cell growth reduction only at high concentrations in vitro and failed to have a significant effect on tumor growth in vivo. The present study confirms over-expression of CA9 in UC and for the first time shows a correlation with molecular subtypes. However, CA9 expression showed no association with the outcome of patients with muscle invasive bladder cancer and inhibition of CA9 did not lead to a consistent inhibition of tumor growth. Based on these data, CA9 exhibits a role neither as a predictive or prognostic marker nor as a therapeutic target in invasive UC.

Identifiants

pubmed: 34083096
pii: S1078-1439(21)00168-X
doi: 10.1016/j.urolonc.2021.04.011
pii:
doi:

Substances chimiques

Antigens, Neoplasm 0
Biomarkers, Tumor 0
Phenylurea Compounds 0
Sulfonamides 0
U-104 0
CA9 protein, human EC 4.2.1.1
Carbonic Anhydrase IX EC 4.2.1.1

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

498.e1-498.e11

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Tilman Todenhöfer (T)

Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada; Eberhard-Karls-University, Tuebingen, Germany; Clinical Trial Unit Studienpraxis Urologie, Nürtingen, Germany. Electronic address: todenhoefer@studienurologie.de.

Ewan A Gibb (EA)

Decipher Biosciences, Vancouver, Canada.

Roland Seiler (R)

Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada; Department of Urology, Inselspital, Bern, Switzerland.

Alireza Kamyabi (A)

Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.

Jörg Hennenlotter (J)

Eberhard-Karls-University, Tuebingen, Germany.

Paul McDonald (P)

British Columbia Cancer Agency, Vancouver, Canada.

Igor Moskalev (I)

Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.

Craig Stewart (C)

Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.

Jian Gao (J)

Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.

Ladan Fazli (L)

Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.

Shoukat Dedhar (S)

British Columbia Cancer Agency, Vancouver, Canada.

Arnulf Stenzl (A)

Eberhard-Karls-University, Tuebingen, Germany.

Htoo Zarni Oo (HZ)

Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.

Peter C Black (PC)

Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH